Skip to Main Content

Paper Details

Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
Hypertens Res
20
2023
Author NameAffiliation
Mason W FreemanCinCor Pharma, Inc.
  • 1 - 1

Datasets

Release 1.2